What is the current share price of Shilpa Medicare Limited (SHILPAMED)?

As of the latest market update, Shilpa Medicare Limited (SHILPAMED) is trading at ₹546.75. The stock has moved 1.47% up in the recent session.

What is the technical sentiment for SHILPAMED stock?

Based on our proprietary technical analysis, the current signal for SHILPAMED is "BUY". This analysis considers over 20+ indicators including RSI, MACD, and moving average crossovers to gauge market momentum.

What is the 52-week high and low for Shilpa Medicare Limited?

Shilpa Medicare Limited has seen a 52-week high of ₹581 and a 52-week low of ₹259.5. Comparing the current price to these levels helps investors understand the stock's relative valuation and volatility over the past year.

Which sector does Shilpa Medicare Limited belong to?

Shilpa Medicare Limited operates in the Healthcare sector, specifically within the Pharmaceuticals & Biotechnology industry. Its performance is often influenced by broader trends in the Healthcare segment.

What is the market capitalization of SHILPAMED?

Shilpa Medicare Limited (SHILPAMED) has a market capitalization of approximately ₹10.69K Cr. This classifies it as a small cap stock in the Indian market.

SHILPAMED

NSE

Shilpa Medicare Limited (SMALL CAP)

Healthcare>Healthcare>Pharmaceuticals & Biotechnology>Pharmaceuticals

₹546.75

7.90 (1.47%)

High VOLATILITY

As on 12 Jun 2026

Advanced Chart

Price History

Market Cap

The total value of all a company's shares of stock. It's a quick way to gauge a company's size and value.

₹10.69K Cr

SMALL CAP

P/E Ratio

Price-to-Earnings ratio. It shows how much you pay for ₹1 of the company's earnings. A lower P/E might mean it's undervalued, but it varies by industry.

43.1

Industry

The specific business sector the company operates in. Useful for comparing with similar companies.

Pharmaceuticals

52-Week Range

The highest and lowest price at which the stock has traded in the last year (52 weeks). It helps show how volatile the stock is and where it is currently priced relative to its recent history.

52W Low₹259.5+110.7%

52W High₹581-5.9%

Current Price

₹546.75

Circuit Limits (20%)

The maximum allowed price movement (up or down) in a single trading day to prevent excessive volatility. If the stock hits these limits, trading may be temporarily halted.

Lower Circuit₹437.40

Upper Circuit₹656.10

Reference Price

₹546.75

Investment Checklist

Rounding Bottom on 1W (BREAKOUT CONFIRMED) — target ₹375.22

Triple Bottom on 1D (BREAKOUT CONFIRMED) — target ₹388.2

Trend: Price above all key MAs — strong uptrend | Bullish MA stack (20>50>200)

Volume divergence: Bearish (price up, volume down)

Composite score 37.46 (BUY) with 84.0% confidence

Technical Analysis

Analysis from 2026-06-12

Confidence

84%

Trend

BULLISH

Price above all key MAs — strong uptrend | Bullish MA stack (20>50>200)

EMA20

512.03

EMA50

463.09

EMA200

408.06

Price Action

UPTREND

BULLISH

Higher Highs6

Higher Lows8

Lower Highs3

Lower Lows1

Support & Resistance Levels

Resistance (Above)

No recent resistance detected

Support (Below)

₹529.80

₹500.00

₹473.72

₹457.50

₹436.40

Volume Analysis

TrendDECREASING

Change-22.80%

Unusual VolumeNo

Divergence Detected

Bearish (price up, volume down)

Stop Loss Levels

Fixed Risk

1% Risk₹541.28

3% Risk₹530.35

5% Risk₹519.41

7% Risk (Custom)

₹508.48

Technical Levels

1x ATR (Volatility)₹520.81

2x ATR (Swing)₹494.87

3x ATR (Trend)₹468.93

Immediate Support₹529.80

Moving Averages

EMA 9 (Short-term)₹536.54

EMA 20 (Medium-term)₹512.03

EMA 50 (Trend)₹463.09

EMA 200 (Long-term)₹408.06

Financials

Financial Analysis

Metric	Mar '25	Jun '25	Sep '25	Dec '25
Revenue	₹330.8 Cr	₹321.5 Cr	₹370 Cr	₹409.7 Cr
Net Profit	₹14.5 Cr	₹46.9 Cr	₹44.1 Cr	₹44.6 Cr
EPS	—	₹2.40	₹1.13	₹2.36
Operating Profit	₹58.6 Cr	₹97.3 Cr	₹109.9 Cr	₹101.9 Cr

ROE

3.31%

ROCE

6.71%

Debt/Equity

0.25

Current Ratio

1.46

OPM

24.87%

NPM

10.88%

Peer Comparison

Pharmaceuticals

Peer Comparison

Symbol	Name	Price	Change
SUNPHARMA	Sun Pharmaceutical Industries Limited	₹1,807.70	+0.75%
DIVISLAB	Divi's Laboratories Limited	₹6,638.00	-0.26%
TORNTPHARM	Torrent Pharmaceuticals Limited	₹4,571.20	-0.02%
CIPLA	Cipla Limited	₹1,389.40	+0.44%
ZYDUSLIFE	Zydus Lifesciences Limited	₹1,104.70	-0.11%
DRREDDY	Dr. Reddy's Laboratories Limited	₹1,275.40	-0.05%
LUPIN	Lupin Limited	₹2,293.30	+0.88%
MANKIND	Mankind Pharma Limited	₹2,381.10	+0.35%
AUROPHARMA	Aurobindo Pharma Limited	₹1,472.80	+0.59%
LAURUSLABS	Laurus Labs Limited	₹1,394.30	+0.25%

Corporate Information

Large Deals

View All

Bulk, Block and Short deals reported for this stock.

Loading Deals...

Corporate Actions

Recent actions

View All

Ex Date	Purpose	Type
03 Oct 2025	Bonus 1:1	BONUS
17 Sept 2025	Dividend - Re 1 Per Share	DIVIDEND
06 Sept 2024	Annual General Meeting	AGM
22 Sept 2023	Annual General Meeting	AGM
19 Sept 2022	Annual General Meeting/Dividend - Rs 1.10 Per Share	AGM

Announcements

Latest updates

View All

Date	Description	Link
03 Jun 2026	Press Release
30 May 2026	General Updates
26 May 2026	Analysts/Institutional Investor Meet/Con. Call Updates
23 May 2026	Copy of Newspaper Publication
23 May 2026	Analysts/Institutional Investor Meet/Con. Call Updates

Board Meetings

Upcoming and past meetings

View All

Date	Purpose	Links
22 May 2026	Financial Results/Dividend
22 May 2026	Board Meeting Intimation	XBRL
06 Feb 2026	Board Meeting Intimation	XBRL
06 Feb 2026	Financial Results
13 Nov 2025	Board Meeting Intimation	XBRL

Corporate Events

Upcoming results & meetings

View All

No upcoming events found

We couldn't find any scheduled corporate actions for this symbol at the moment.

Shareholding Pattern

As of Dec 2025Pledged: 8.73%

Current Distribution

Trend (Last 8 Qtrs)

Latest News

News for SHILPAMED

View All

NEWS

neutral

Business Standard - Markets 10d ago

Shilpa Biocare to acquire 30.4% stake in Barcelona-based Gate2Brain

Shilpa Medicare announced that its wholly owned subsidiary, Shilpa Biocare intends to make a strategic equity partnership of 30.4% in Gate2Brain. The investment of Euro 7 million includes cash infusion of Euro 0.5 million, equity for services Euro 5.5 million and Euro 1 million for development of project.

BFINVESTSHILPAMEDFinancial ServicesHealthcare

Read full story

Shilpa Medicare to acquire 30.4% stake in Spain's Gate2Brain with €7 million investment

neutral

CNBC TV18 - Markets 10d ago

Shilpa Medicare to acquire 30.4% stake in Spain's Gate2Brain with €7 million investment

The global glioblastoma treatment market is estimated at approximately $3 billion in 2025 and is projected to exceed $6 billion by 2035. The pediatric brain tumour market is estimated at around $1.5 billion, while the market for DIPG therapies is expected to reach nearly $1.2 billion by 2035.

BFINVESTGLOBALSHILPAMEDConsumer ServicesFinancial Services

Read full story

NEWS

positive

Business Standard - Markets 21d ago

Shilpa Medicare consolidated net profit rises 642.87% in the March 2026 quarter

Sales rise 32.09% to Rs 436.99 crore

SHILPAMEDHealthcare

Read full story

SHILPAMED

Price History

Investment Checklist

Technical Analysis

Technical Analysis

Trend

Price Action

Support & Resistance Levels

Volume Analysis

Stop Loss Levels

Fixed Risk

Technical Levels

Moving Averages

Financials

Financial Analysis

Peer Comparison

Peer Comparison

Corporate Information

Large Deals

Corporate Actions

Announcements

Board Meetings

Corporate Events

Shareholding Pattern

Shareholding Pattern

Current Distribution

Trend (Last 8 Qtrs)

Latest News

News for SHILPAMED

Shilpa Biocare to acquire 30.4% stake in Barcelona-based Gate2Brain

Shilpa Medicare to acquire 30.4% stake in Spain's Gate2Brain with €7 million investment

Shilpa Medicare consolidated net profit rises 642.87% in the March 2026 quarter

Frequently Asked Questions

What is the current share price of Shilpa Medicare Limited (SHILPAMED)?

What is the technical sentiment for SHILPAMED stock?

What is the 52-week high and low for Shilpa Medicare Limited?

Which sector does Shilpa Medicare Limited belong to?

What is the market capitalization of SHILPAMED?